Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-10-2008 | Article

Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children

Authors: B. Mikoluc, H. Kayhty, E. Bernatowska, R. Motkowski

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2008

Abstract

The aim of the study was to determine the concentration of pneumococcal antibodies after a dose of 7-valent pneumococcal conjugate vaccine (PCV7) in 30 asplenic children between 4 months and 19 years of age. Fifteen children had received pneumococcal polysaccharide vaccine (PPV) approximately 5 years prior to vaccination with PCV7. The antibody concentrations against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were measured by ELISA before and after the PCV7 vaccination. Before vaccination with PCV7, the antibody concentrations were similar in children who had or had not received PPV previously. A dose of PCV7 stimulated a good immune response in asplenic patients. Prior immunization with PPV did not affect the antibody concentration after the vaccination with PCV7. In conclusion, asplenic children vaccinated with PPV may need revaccination with PPV earlier than the recommended 3–5 years after the first dose. PCV7 induces a satisfactory immune response in asplenic patients and should be considered as an alternative vaccine in that patient group.

Dickerman JD (1979) Splenectomy and sepsis: a warning. Pediatrics 63:938–941PubMed

Singers DB (1973) Postsplenectomy sepsis. Perspect Pediatr Pathol 1:285–311

Lynch AM, Kapila R (1996) Overwhelming postsplenectomy infection. Infect Dis Clin North Am 10:693–707PubMedCrossRef

Sumaraju V, Leon G, Smith SM (2001) Infectious complications in asplenic hosts. Infect Dis Clin North Am 15:551–565PubMedCrossRef

Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. I. Clin Infect Dis 30:100–121PubMedCrossRef

Schutze GE, Mason EO, Barson WJ et al (2002) Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J 21:278–282PubMedCrossRef

Lutwick LI (2000) Infections in asplenic patients. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious disease. Churchill Livingstone, Philadelphia, pp 3169–3176

Davidson RN, Wall RA (2001) Prevention and management of infection in patients without a spleen. Clin Microbiol Infect 7:657–666PubMedCrossRef

American Academy of Pediatrics (2006) Immunocompromised children—asplenic children. The Red Book on CD-ROM, Report of the Committee on Infectious Disease, 27th edn. American Academy of Pediatrics, Elk Grove Village

10.

Melles DC, de Marie S (2004) Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 62(2):45–52PubMed

11.

Cullingford GL, Watkins DN, Watt AD, Mallon DF (1991) Severe late postsplenectomy infection. Br J Surg 78:716–721PubMedCrossRef

12.

Williams DN, Kaur B (1996) Postsplenectomy care. Strategies to decrease the risk of infection. Postgrad Med 100(1):195–198PubMedCrossRef

13.

Brigden ML (2001) Detection, education and management of the asplenic or hyposplenic patient. Am Family Physician 63(3):499–506

14.

Castagnola E, Fioredda F (2003) Prevention of life-threatening infections due to encapsula bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol 71:319–326PubMedCrossRef

15.

ACIP (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9):1–35

16.

Canadian Pediatrics Society (1999) Prevention and therapy of bacterial infections for children with asplenia or hyposplenia. Paediatr Child Health 4(6):417–421

17.

World Health Organization (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Se 927(Annex 2):64–98

18.

Black S, Shinefield H, Fireman B et al (2000) Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Am J Manag Care 6 [10 Suppl]:536–549

19.

Pedersen FK, Nielsen JL, Ellegaard J (1982) Antibody response to pneumococcal vaccine in splenectomized adults and adolescents. Acta Pathol Microbiol Immunol Scand 90:257–263

20.

Giebnik GS, Le CT, Cosio FG et al (1981) Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 3 [Suppl]:168–178

21.

Sullivan JL, Ochs HD, Schiffman G et al (1978) Immune response after splenectomy. Lancet 1(8057):178–181PubMedCrossRef

22.

Caplan ES, Boltansky H, Schnyder MJ et al (1983) Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J Trauma 23(9):801–805PubMed

23.

Siber GR (1997) Methods for estimating serologic correlates of protection. Dev Biol Stand 89:283–296PubMed

24.

Robbins JB, Austrian R, Lee CJ et al (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148:1136–1159PubMed

25.

Sleeman K, Knox K, George R et al (2001) Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183:239–246PubMedCrossRef

26.

Shurin PA, Rehmus JM, Johnson CE et al (1993) Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 123:801–810PubMedCrossRef

27.

Jugenburg M, Haddock G, Freedman MH et al (1999) The morbidity and mortality of pediatric post splenectomy: does prophylaxis make a difference? J Pediatr Surg 34(7):1064–1067PubMedCrossRef

28.

Skoczynska A, Hryniewicz W (2003) Genetic relatedness, antibiotic susceptibility, and serotype distribution of Streptococcus pneumoniae responsible for meningitis in Poland, 1997–2001. Microb Drug Resist 9(2):175–182PubMedCrossRef

29.

Finn A, Booy R, Moxon R et al (2002) Should the new pneumococcal vaccine be used in high-risk children? Arch Dis Child 87:18–21PubMedCrossRef

30.

Sulikowska A, Grzesiowski P, Sadowy E et al (2004) Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated from the nasopharynges of asymptomatic children and molecular analysis of S. pneumoniae and H. influenzae strain replacement in the nasopharynx. J Clin Microbiol 42(9):3942–3949PubMedCrossRef

31.

American Academy of Pediatrics (2000) Committee on infectious diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevenar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106(2):362–366CrossRef

32.

Nachman S, Kim S, King J, Abrams EJ et al (2003) Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 112(1):66PubMedCrossRef

Title: Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children
Authors: B. Mikoluc
H. Kayhty
E. Bernatowska
R. Motkowski
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-008-0523-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2008

The clinical diagnosis of Mycoplasma pneumoniae: the diagnostic importance of highly elevated serum cold agglutinins

Pulmonary Mycobacterium simiae infection: comparison with pulmonary tuberculosis

Disseminated cutaneous and pulmonary abscesses in an injecting drug user caused by a Panton-Valentine leucocidin-positive, methicillin-susceptible Staphylococcus aureus strain

The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa

Leishmaniases in Northern Greece: seroprevalence of the infection and incidence of the disease during the period 2001–2006

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials